(Q34326550)

1 August 2017

1 reference

title

Targeted therapy for multiple myeloma (English)

1 reference

1 August 2017

Anderson KC

1

1 reference

1 August 2017

1 July 2001

1 reference

1 August 2017

Seminars in Hematology

1 reference

1 August 2017

38

1 reference

1 August 2017

286-294

1 reference

1 August 2017

3

1 reference

T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect

1 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Role of interleukin 6 in the growth of myeloma-derived cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Apoptosis in multiple myeloma: therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Oncostatin M induces association of Grb2 with Janus kinase JAK2 in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Cytochrome c-dependent and -independent induction of apoptosis in multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Novel therapeutic targets in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Proteasome inhibition: A novel mechanism to combat asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Anti-B4-blocked ricin: a phase II trial of 7 day continuous infusion in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Cell surface expression and functional significance of adhesion molecules on human myeloma-derived cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

How proteolysis drives the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

NF-kappa B regulates VCAM-1 expression on fibroblast-like synoviocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

p53-dependent induction of apoptosis by proteasome inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growth

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Lack of a role of interleukin 11 in the growth of multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Thalidomide--a revival story

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

A multiple cytokine- and second messenger-responsive element in the enhancer of the human interleukin-6 gene: similarities with c-fos gene regulation

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Kaposi's sarcoma-associated herpesvirus infection of bone marrow dendritic cells from multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Expression of interleukin-1beta and tumour necrosis factor-alpha in plasma cells from patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Monoclonal Antibody-Purged Bone Marrow Transplantation Therapy for Multiple Myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

CD6+ T cell-depleted allogeneic bone marrow transplantation for non-Hodgkin’s lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Treatment of multiple myeloma by antibody mediated immunotherapy and induction of myeloma selective antigens.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990021-6

7 January 2021

10.1016/S0037-1963(01)90021-6

Identifiers

DOI

1 reference

1 August 2017

1 reference

PubMed ID

11486317